About Inozyme Pharma
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
|
|
|
51-200 employees
View all Inozyme Pharma employees
|
|
Biotechnology
|
|
$10M–$50M
|
|
(617) 864-1000
|
|
321 Summer St, Suite 400, Boston, Massachusetts 02210, US
|
|
2016
|
Inozyme Pharma Alternatives
Frequently Asked Questions about Inozyme Pharma
Doug Treco is the CEO of Inozyme Pharma. To contact Doug Treco email at [email protected] or [email protected]. Or you may call 617-401-4062
The decision makers in Inozyme Pharma are Andrea Belschner, Axel Bolte, Catherine Nester, etc. Click to Find Inozyme Pharma decision makers emails.
Inozyme Pharma headquarters is located at 321 Summer St, Suite 400, Boston, Massachusetts 02210, US.
Inozyme Pharma generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact Inozyme Pharma by calling (617) 864-1000.
Inozyme Pharma Staff Directory
Search Inozyme Pharma Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
